

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Number: U.S. 7,285,564 B2)	
)	
Application No.: 10/696,464)	Confirmation Number: 5983
)	
Issue Date: October 23, 2007)	
)	
Inventor(s): Mathai MAMMEN et al.)	
)	
Title: SUBSTITUTED 4-AMINO-1-)	
(PYRIDYLMETHYL)PIPERIDINE)	
AND RELATED COMPOUNDS)	

REQUEST FOR CERTIFICATE OF CORRECTION

ATTN: Certificate of Correction Branch

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Assignee of record hereby requests that the Director issue a certificate of correction for the above-identified patent to correct one or more mistakes. The requested corrections are shown on the attached Form PTO/SB/44 (2 pages).

A. Requested Corrections

A certificate of correction is requested to correct the following mistakes:

a. Office Mistakes – 37 C.F.R. §1.322

(1) In column 77, at line 13, "-CH²-R⁵" should read "-CH₂-R⁵" (shown correctly at page 3, line 2, of the amendment filed on March 30, 2007).

(2) In column 77, at line 23, "C₂₋₄ alkynyl" should read "C₂₋₆ alkynyl" (shown correctly at page 3, line 9, of the amendment filed on March 30, 2007).

(3) In column 78, at line 6, “C₂₋₄ alkynyl” should read “C₂₋₆ alkynyl” (shown correctly at page 4, line 13, of the amendment filed on March 30, 2007).

(4) In column 80, at line 1, “-(CH²)_x-phenyl” should read “-(CH₂)_x-phenyl” (shown correctly at page 7, line 20, of the amendment filed on March 30, 2007).

(5) In column 81, at line 12, “C₂-alkenyl” should read “C₂₋₆ alkenyl” (shown correctly at page 10, line 6, of the amendment filed on March 30, 2007).

(6) In column 81, at line 59, “C₂₋₄ alkyl” should read “C₂₋₄ alkynyl” (shown correctly at page 11, line 8, of the amendment filed on March 30, 2007).

(7) In column 83, at line 3, “-CH²-R⁵” should read “-CH₂-R⁵” (shown correctly at page 13, line 8, of the Amendment filed on March 30, 2007).

b. Applicant Mistakes – 37 C.F.R. §1.322

(1) In column 77, at lines 21, 31 and 67, “substitutents” should read “substituents”. This is a typographical error.

(2) In column 78, at lines 4, 13, 20, 27, 29, 46 and 57, “substitutents” should read “substituents”. This is a typographical error.

(3) In column 81, at lines 21, 31 and 62, “substitutents” should read “substituents”. This is a typographical error.

(4) In column 82, at lines 2, 4 and 13, “substitutents” should read “substituents”. This is a typographical error.

(5) In column 83, at lines 11, 42, 49, 51 and 61, “substitutents” should read “substituents”. This is a typographical error.

These mistakes occurred in good faith, and correction of these mistakes is not believed to involve a change in the patent that would constitute new matter or that would require re-examination.

B. Fee Payment

The Director is authorized to charge the requisite fee under §1.20(a) and any other necessary fees, and to credit any overpayments, to Deposit Account No. 50-0344 in the name of Theravance, Inc.

C. Mailing Address for Certificate

The certificate of correction should be sent to:

Jeffrey A. Hagenah, Ph.D.
Theravance, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080

Any questions regarding this paper should be addressed to the undersigned attorney for assignee.

Respectfully submitted,
THERAVANCE, INC.

Date: February 4, 2009

/Jeffrey A. Hagenah/
Jeffrey A. Hagenah, Ph.D.
Reg. No. 35,175
(650) 808-6406

Correspondence Address:
THERAVANCE, INC.

Attn: Patent Dept.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000; Fax: (650) 808-6078

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,285,564 B2

APPLICATION NO.: 10/696,464

ISSUE DATE : October 23, 2007

INVENTOR(S) : Mathai Mammen et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 77

at line 13, “-CH²-R⁵” should read “-CH₂-R⁵”

at lines 21, 31 and 67, “substitutents” should read “substituents”

at line 23, “C₂₋₄ alkynyl” should read “C₂₋₆ alkynyl”

Column 78

at lines 4, 13, 20, 27, 29, 46 and 57, “substitutents” should read “substituents”

at line 6, “C₂₋₄ alkynyl” should read “C₂₋₆ alkynyl”

Column 80

at line 1, “-(CH²)_x-phenyl” should read “-(CH₂)_x-phenyl”

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Theravance, Inc. - Patent Department
901 Gateway Blvd.
South San Francisco, CA 94080

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 2 of 2

PATENT NO. : 7,285,564 B2
APPLICATION NO.: 10/696,464
ISSUE DATE : October 23, 2007
INVENTOR(S) : Mathai Mammen et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 81

at line 12, "C₂-alkenyl" should read "C₂₋₆ alkenyl"

at lines 21, 31 and 62, "substitutents" should read "substituents"

at line 59, "C₂₋₄ alkyl" should read "C₂₋₄ alkynyl"

Column 82

at lines 2, 4 and 13, "substitutents" should read "substituents"

Column 83,

at line 3, "-CH²-R⁵" should read "-CH₂-R⁵"

at lines 11, 42, 49, 51 and 61, "substitutents" should read "substituents"

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Theravance, Inc. - Patent Department
901 Gateway Blvd.
South San Francisco, CA 94080

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.